Effect of repeated co-treatment with fluoxetine and amantadine on the behavioral reactivity of the central dopamine and serotonin system in rats

Pharmacological Reports

Volumn 61, Issue 5, 2009, Pages 924-929

  Rogóz, Zofia ^a   Skuza, Grazyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Amantadine; Behavioral test; Fluoxetine; Rats; Repeated treatment

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; AMANTADINE; FLUOXETINE; QUINPIROLE; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; BEHAVIORAL RESEARCH; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TARGETING; EVOKED RESPONSE; HEAD TWITCH; HYPERACTIVITY; LOCOMOTION; NONHUMAN; RAT; REPEATED DRUG DOSE; RETREATMENT; SEROTONINERGIC SYSTEM; TREATMENT DURATION;

EID: 70549098276     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(09)70150-1     Document Type: Article

References (29)

1. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000, 47, 351-354. (Pubitemid 30109248)
2. D'Aquila PS, Collu M, Gessa GL, Serra G: The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol, 2000, 405, 365-373. (Pubitemid 30734193)
3. Eltze M: Multiple mechanisms of action: the pharmacological profile of budipine. J Neural Transm, Suppl, 1999, 56, 83-105.
4. Fisher A, Starr MS: Opposite effects of glutamate antagonists and antiparkinsonian drugs on the activities of DOPA decarboxylase and 5-HTP decarboxylase in the rat brain. Brain Res, 2000, 868, 268-274.
5. Maj J, Bijak M, Dziedzicka-Wasylewska M, Rogóż Z, Skuza G, Tokarski K: The effect of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology, 1996, 127, 73-82. (Pubitemid 26285685)
6. Maj J, Dziedzicka-Wasylewska M, Rogoż R, Rogóż Z: Effect of antidepressant drugs administered repeatedly on the dopamine D receptors in the rat brain. Eur J Pharmacol, 1998, 351, 31-37. (Pubitemid 28300300)
7. Maj J, Moryl E: Effect of fluoxetine given chronically on the responsiveness of 5-HT receptor subpopulations to their agonists. Eur Neuropsychopharmacol, 1993, 3, 85-94. (Pubitemid 24089497)
8. Maj J, Moryl E: Effect of sertraline and Citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations. J Neural Transm [Gen Sect], 1992, 88, 143-156.
9. Maj J, Rogóż Z, Skuza G, Sowińska H: The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonist, in the forced swimming test. Pol J Pharmacol, 1992, 44, 337-346. (Pubitemid 23009661)
10. Moryl E, Danysz W, Quack G: Potential antidepressive properties of amantadine, memantine and bifemelane. Pharmacol Toxicol, 1993, 72, 394-397. (Pubitemid 23188507)
11. Nibuya M, Morinobu S, Duman RS: Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci, 1995, 15, 7539-7547.
12. Nordheim Alme M, Wibrand K, Dagestad G, Bramham CR: Chronic fluoxetine treatment induces brain region-specific upregulation of genes assiociated with BDNF-induced long-term potentiation. Neural Plast, 2007, 2007, 1-9.
13. Owen JCE, Whitton PS: Effect of amantadine and budipine on antidepressant drug-evoked changes in extracellular 5-HT in the frontal cortex of freely moving rats. Br J Pharmacol, 2005, 145, 587-592.
14. Owen JCE, Whitton PS: Effect of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats. Brain Res, 2006, 1117, 206-212.
15. Papp M, Moryl E: Antidepressant activity of uncompetitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression. Eur J Pharmacol, 1994, 263, 1-7. (Pubitemid 24290246)
16. Poleszak E, Wlaz P, Wróbel A, Dybala M, Sowa M, Fidecka S, Pilc A, Nowak G: Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effect in the forced swim test. Pharmacol Rep, 2007, 59, 595-600.
17. Porter RH, Greenamyre JT: Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem, 1995, 64, 614-623.
18. Rogóż Z, Dziedzicka-Wasylewska M, Daniel WA, Wójcikowski J, Dudek D, Wróbel A, Zieba A: Effects of joint administration of Imipramine and amantadine in patients with drug-resistant unipolar depression. Pol J Pharmacol, 2004, 56, 735-742. (Pubitemid 40287475)
19. Rogóż Z, Skuza G, Daniel WA, Wójcikowski J, Dudek D, Wróbel A: Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacol Rep, 2007, 59, 778-784.
20. Rogóż Z, Skuza G, Legutko B: Repeated co-treatment with fluoxetine and amantadine induces brain-derived neurotrophic factor gene expression in rats. Pharmacol Rep, 2008, 60, 817-826.
21. Rogóż Z, Skuza G, Legutko B: Repeated co-treatment with Imipramine and amantadine induces hippocampal brain-derived neurotrophic factor gene expression in rats. J Physiol Pharmacol, 2007, 58, 219-234. (Pubitemid 47026558)
22. Rogóż Z, Skuza G, Maj J, Danysz W: Synergistic effect of uncompetitive NMDA receptor antagonists and antidepressant drugs in the forced swimming test in rats. Neuropharmacology, 2002, 42, 1024-1030. (Pubitemid 34790257)
23. Skolnik P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31-40.
24. Stryjer R, Strous RD, Shaked G, Bar F, Feldman B, Kotler M, Polak L: Amantadine as augmentation therapy in the management of treatment-resistant depression. Int Clin Psychopharmacol, 2003, 18, 93-96.
25. Trullas R, Skolnik P: Functional antagonists of the NMDA receptor complex exhibit antidepressant action. Eur J Pharmacol, 1990, 185, 1-10. (Pubitemid 20254891)
26. Vetulani J, Nalepa I: Antidepressants: past, present, and future. Eur J Pharmacol, 2000, 405, 351-363.
27. Willner P: The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol, 1997, 12, Suppl 3, S7-S14.
28. Zaniewska M, McCreary AC, Sezer G, Przegalinski E, Filip M: Effects of agmatine on nicotine-evoked behavioral responses in rats. Pharmacol Rep, 2008, 60, 645-654.
29. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006, 63, 856-864. (Pubitemid 44188478)